Bernard Ravina

Bernard Ravina is a Johns Hopkins-trained neurologist who spent two decades treating people with dystonia before deciding the field needed a drug that did not yet exist. In 2025 he founded Vima Therapeutics in Cambridge, Massachusetts, and is its CEO, advancing VIM0423, a once-daily oral therapy aimed at the dopamine-acetylcholine imbalance behind movement disorders. The company emerged from stealth with a $60 million Series A, later extended to $100 million, and dosed its first Phase 2 dystonia patient in March 2026.